Inactive Instrument

Press Releases Ambrx Biopharma Inc. Nasdaq

Equities

Ambrx Shareholders Approve Acquisition by Johnson & Johnson	03-06	AQ
AMAM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Ambrx Biopharma to Johnson & Johnson	01-08	AQ
Ambrx Announces Sale to Johnson & Johnson	01-08	AQ
Ambrx to be added to the NASDAQ Biotechnology Index	12-15	AQ
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)	12-14	AQ
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer	11-28	AQ
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who progressed on Multiple FDA-Approved Treatments	24/10/23	AQ
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments	23/10/23	AQ
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress	16/10/23	AQ
Ambrx Biopharma : ESMO 2023 Abstracts Available Here	15/10/23	PU

No results for this search